Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Sarah Cowlishaw Named to The Lawyer “Hot 100”

January 28, 2020

LONDON—The Lawyer has named London life sciences partner Sarah Cowlishaw to its “Hot 100,” a list that recognizes the most daring, innovative and creative lawyers from in-house, private practice and the Bar around the U.K.

The Lawyer highlighted Ms. Cowlishaw’s work for biotech company Sensyne Health on regulatory matters related to its AIM IPO and her ongoing counsel to the company on its contracts to operate its digital health and AI platforms for a number of UK National Health Service Trusts. The feature also included her representation of GlaxoSmithKline on its collaboration with genetics company 23andMe to develop new medicines using genetics as a basis for discovery.

Ms. Cowlishaw practices life sciences regulatory and commercial law and is a member of Covington’s Food, Drug, and Device Practice. She advises major pharmaceutical companies, as well biotechnology, diagnostic, medical device, and consumer product manufacturers, on a wide range of regulatory, compliance, transactional, and legislative matters. On the commercial side, her expertise covers the full range of issues that span the product life-cycle in the life sciences sector, including clinical trial agreements, manufacturing and supply agreements, distribution and other marketing agreements, and regulatory services agreements. In addition, she has particular experience in digital health matters from both a regulatory and commercial perspective.

Share this article: